Back to Search Start Over

Nuclear Proteomics of Induced Leukemia Cell Differentiation.

Authors :
Novikova, Svetlana
Tolstova, Tatiana
Kurbatov, Leonid
Farafonova, Tatiana
Tikhonova, Olga
Soloveva, Natalia
Rusanov, Alexander
Archakov, Alexander
Zgoda, Victor
Source :
Cells (2073-4409). Oct2022, Vol. 11 Issue 20, p3221-N.PAG. 21p.
Publication Year :
2022

Abstract

Studies of induced granulocytic differentiation help to reveal molecular mechanisms of cell maturation. The nuclear proteome represents a rich source of regulatory molecules, including transcription factors (TFs). It is important to have an understanding of molecular perturbations at the early stages of the differentiation processes. By applying the proteomic quantitative profiling using isobaric labeling, we found that the contents of 214, 319, 376, 426, and 391 proteins were altered at 3, 6, 9, 12, and 72 h, respectively, compared to 0 h in the HL-60 cell nuclear fraction under all-trans-retinoid acid (ATRA) treatment. From 1860 identified nuclear proteins, 231 proteins were annotated as proteins with transcription factor (TF) activity. Six TFs (RREB1, SRCAP, CCDC124, TRIM24, BRD7, and BUD31) were downregulated and three TFs EWSR1, ENO1, and FUS were upregulated at early time points (3–12 h) after ATRA treatment. Bioinformatic annotation indicates involvement of the HL-60 nuclear proteome in DNA damage recognition in the RUNX1-triggered pathway, and in the p53-regulation pathway. By applying scheduled multiple reaction monitoring using stable isotopically labeled peptide standards (MRM/SIS), we found a persistent increase in the content of the following proteins: PRAM1, CEPBP, RBPJ, and HIC1 in the HL-60 cell nuclear fraction during ATRA-induced granulocytic differentiation. In the case of STAT1, CASP3, PARP1, and PRKDC proteins, a transient increase in their content was observed at early time points (3–12 h) after the ATRA treatment. Obtained data on nuclear proteome composition and dynamics during granulocytic differentiation could be beneficial for the development of new treatment approaches for leukemias with the mutated p53 gene. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20734409
Volume :
11
Issue :
20
Database :
Academic Search Index
Journal :
Cells (2073-4409)
Publication Type :
Academic Journal
Accession number :
159910188
Full Text :
https://doi.org/10.3390/cells11203221